Work

Bone biomarkers and overall survival (OS) in men with advanced hormone-sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of ADT +/- orteronel.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.5071

Authors: Primo "Lucky" N. Lara, Edward Mayerson, Erik Gertz, Catherine Tangen, Amir Goldkorn, Marta Van Loan, Maha H. A. Hussain, Shilpa Gupta, Jingsong Zhang, Mamta Parikh, Przemyslaw Twardowski, David I. Quinn, Nicholas J. Vogelzang, Ian M Thompson, Neeraj Agarwal

Institutions: University of California System, United States Department of Agriculture, Western Human Nutrition Research Center, Fred Hutch Cancer Center, University of Southern California, USC Norris Comprehensive Cancer Center, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Cleveland Clinic, Moffitt Cancer Center, UC Davis Comprehensive Cancer Center, City Of Hope National Medical Center, Comprehensive Cancer Centers of Nevada, Children's Hospital of San Antonio, University of Utah, Huntsman Cancer Institute

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Institutes of Health

OpenAlex ID: W4286295682

Cites:

Cited by: 2

Related to: 10